Loading...
XSHG603387
Market cap554mUSD
Jan 10, Last price  
8.01CNY
1D
1.91%
1Q
-2.55%
IPO
-12.65%
Name

Getein Biotech Inc

Chart & Performance

D1W1MN
XSHG:603387 chart
P/E
14.52
P/S
2.97
EPS
0.55
Div Yield, %
5.40%
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
14.81%
Revenues
1.37b
-24.85%
73,640,347154,195,412210,293,366276,420,264369,090,356488,582,766686,238,289968,204,2851,123,335,6181,401,701,3861,821,860,7031,369,162,256
Net income
280m
-43.92%
21,960,30765,627,76175,135,877105,066,842138,356,904193,988,370249,612,047339,672,020304,733,135398,990,048498,909,980279,771,914
CFO
342m
-29.10%
23,799,01359,715,98498,534,931121,729,000155,914,635191,912,890187,097,698225,732,761185,468,524432,364,576482,957,526342,439,889
Dividend
Sep 19, 20240.09 CNY/sh
Earnings
May 22, 2025

Profile

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic products in China and internationally. The company provides diagnostic reagents and analyzers; calibrators; reagent raw materials, such as monoclonal and polyclonal antibodies, antigen, antiserum, and microsphere; and cardiac marker, inflammation, renal function, coagulation, thyroid function, fertility, diabetes care, and thrombus products. It also offers products in the area of cardiovascular, inflammatory, diabetes, fertility, renal, liver, and others. The company was founded in 2002 and is headquartered in Nanjing, China.
URL
https://www.getein.com.cn/
IPO date
Jul 17, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,369,162
-24.85%
1,821,861
29.97%
Cost of revenue
1,039,061
1,197,793
Unusual Expense (Income)
NOPBT
330,102
624,068
NOPBT Margin
24.11%
34.25%
Operating Taxes
20,861
56,034
Tax Rate
6.32%
8.98%
NOPAT
309,240
568,033
Net income
279,772
-43.92%
498,910
25.04%
Dividends
(219,405)
(123,166)
Dividend yield
3.92%
1.94%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
641,287
583,366
Long-term debt
5,426
12,304
Deferred revenue
20,881
23,466
Other long-term liabilities
1,523
911
Net debt
(53,519)
(561,718)
Cash flow
Cash from operating activities
342,440
482,958
CAPEX
(258,128)
Cash from investing activities
(356,827)
Cash from financing activities
(145,876)
FCF
127,403
33,526
Balance
Cash
936,240
1,157,388
Long term investments
(236,008)
Excess cash
631,774
1,066,295
Stockholders' equity
2,202,946
2,371,392
Invested Capital
2,775,877
2,178,956
ROIC
12.48%
33.21%
ROCE
9.61%
19.10%
EV
Common stock shares outstanding
508,676
507,154
Price
11.00
-12.00%
12.50
-12.77%
Market cap
5,595,438
-11.74%
6,339,419
-12.88%
EV
5,723,843
5,959,830
EBITDA
423,186
694,419
EV/EBITDA
13.53
8.58
Interest
17,482
16,607
Interest/NOPBT
5.30%
2.66%